50th week of 2015 patent applcation highlights part 8 |
Patent application number | Title | Published |
20150352010 | PILL PACK - Some aspects of the invention include a card for a MARS pill pack and tag. The card has a cut-out open to an edge of the card or an aperture spaced from edges of the card for receiving the tag, with contacts arrayed at one side at least of the cut-out or aperture. The card has at least one formation in the card at at least one other side of the cut out or a tag backing strip extending at a side of the aperture opposite from the one side, the formation(s) or the tag backing strip being provided to hold the tag against movement parallel to the card whereby tag contacts are retained in contact with the card contacts in use. | 2015-12-10 |
20150352011 | Abuse Potential Reduction in Abusable Substance Dosage Form - The potential for substance abuse involving residual amounts of abusable substances remaining in used skin-worn patches is reduced by the provision of a system and method for combining the abusable substance with a separate anti-abuse substance agent as part of a removal or disposal procedure. | 2015-12-10 |
20150352012 | OVERCAP INTENDED FOR A PHARMACEUTICAL CONTAINER - The present invention relates to an overcap intended for a pharmaceutical container, in particular a container for an infusion solution or an injection solution, having a receptacle containing at least one preproduced closure stopper accommodated therein, the stopper consisting of a soft plastic material, optionally after pulling off a protective covering, for insertion of a withdrawal cannula, a spike and/or a transfer set. | 2015-12-10 |
20150352013 | NEEDLE KIT - Asceptic transfer through a needle penetrating a septum is accomplished by inserting an elongate inner tube through the needle and delivering a product fluid through the inner tube. Inner tube is desirably made from a polymer such as PTFE and product fluid does not contact the needle. | 2015-12-10 |
20150352014 | Jejunal Feeding Tube And Delivery System - A delivery apparatus and related method for delivering a gastrointestinal device includes a gastrointestinal device (e.g., a delivery or feeding tube) having a lumen to provide a conduit into the digestive tract, from a location external to the digestive tract. The apparatus includes an inner shaft slidably disposed within the lumen of the gastrointestinal device. The shaft is configured to pass through a length of the intestines and to deliver the gastrointestinal device. An atraumatic element (e.g., a ball or balloon) is distal to and coupled to a distal tip of the inner shaft. The atraumatic element can be releasably coupled to the distal tip of the inner shaft. For example, the delivery apparatus can include a release mechanism that releasably engages the atraumatic element to retain the atraumatic element on the distal tip of the shaft. The gastrointestinal device can be configured to extend through and couple to a port, such as a percutaneous endoscopic gastrostomy (PEG) tube. | 2015-12-10 |
20150352015 | HAIR COSMETIC PRODUCT - A hair treatment method entailing sequentially (i) preparing a hair cosmetic by mixing a first agent containing an alkali agent and a second agent containing hydrogen peroxide to form a mixed liquid, (ii) discharging the mixed liquid in the form of a foam from a foamer vessel without a propellant, (iii) applying the mixed liquid to hair, (iv) allowing the mixed liquid to stand for 3 to 60 minutes; and (v) rinsing the mixed liquid away. | 2015-12-10 |
20150352016 | META-STABLE COSMETIC OR SKIN CARE COMPOSITION - A meta-stable composition, a product including the meta-stable composition, and a method of protecting a keratinous substrate from UV radiation by applying the product are provided. The meta-stable cosmetic composition includes at least one water-in-oil emulsifier having a hydrophilic-lipophilic balance (HLB) of less than 6, at least one non-ionic oil-in-water emulsifier having an HLB of greater than 9, at least one ionic surfactant, and at least one skin care active ingredient. The weight ratio of the at least one non-ionic oil-in-water emulsifier to the at least one water-in-oil emulsifier is about 0.02 to about 2.0. The meta-stable cosmetic composition converts from an oil-in-water (O/W) emulsion to a water-in-oil (W/O) emulsion upon rubbing. | 2015-12-10 |
20150352017 | MULTI-PURPOSE COSMETIC WATER-IN-SILICONE EMULSION - Disclosed is a water-in-silicone emulsion and methods for its use that includes 5% to 8% w/w of octinoxate, 1% to 3% w/w of niacinamide, 0.01% to 0.1% w/w of | 2015-12-10 |
20150352018 | ENCODED PARTICLES COMPOSITIONS - The present invention provides a composition comprising at least one type of irradiated crystals and an aqueous preparation. The aforementioned irradiated crystals are exposed to a changing electromagnetic field. The present invention further relates to methods and processes for preparing and using the compositions. | 2015-12-10 |
20150352019 | Dentrifrice Compositions Having Dental Plaque Mitigation or Improved Fluoride Uptake - Dentifrice compositions with high water, a calcium-containing abrasive and polyethylene glycol have an alkaline pH and provide improved anti-plaque benefits with an alkaline pH. | 2015-12-10 |
20150352020 | COMPOSITIONS AND METHODS FOR PRODUCING STABLE NEGATIVE OXIDATION REDUCTION POTENTIAL IN CONSUMABLE MATERIALS - Compositions of reducing agents and carriers for producing a stable negative oxidation reduction potential in consumable materials are disclosed and claimed. Compositions of the invention find use in enhancing the hydration and anti-oxidant value of consumable materials such as foods, beverages and cosmetics, for example. Compositions of the invention also find use in water treatment, agricultural and scientific research applications. Methods for using and making the compositions are also within the scope of the invention. | 2015-12-10 |
20150352021 | FUNCTIONAL NONWOVEN FABRIC AND MANUFACTURING METHOD THEREFOR - Provided is a functional nonwoven fabric that has good feeling upon use, such as hand feeling (softness) or texture, and is capable of stably exhibiting the characteristics of hydroxyapatite (for example, microbe adsorption property). | 2015-12-10 |
20150352022 | Cosmetic Compositions and Methods For Inhibiting Melanin Synthesis - A cosmetic composition suitable for topical application, for example, is provided. In some examples, the cosmetic composition may include undecylenoyl phenylalanine, hexyldecanol, and bisabolol. A method of reducing the synthesis of melanin by using said cosmetic compositions is also disclosed herein. | 2015-12-10 |
20150352023 | PERIODONTAL DISEASE TREATMENT - The present invention for the first time discloses a method and a kit of parts for treating a periodontal disease, such as periimplantitis, gingivitis, periodontitis and/or periimplant mucositis, caused by microorganisms that colonize a tooth and/or implant surface at, above and/or below the gingival margin, and which reside in a biofilm either subgingival and/or supragingival, characterized by employing a surgical process leading to substantively removing, destroying, killing and/or disrupting and/or inhibiting growth and/or regrowth of a pathogenic biofilm at a site of a microbial infection in a patient suffering from a periodontal disease. Said method comprises, and said kit of parts comprises the means for; cleaning disinfecting and/or debriding the site of microbial infection mechanically and sequentially using first at least one cleaning and/or disinfecting agent with an immediate bactericidal effect, such as a NaClO solution, and thereafter at least one cleaning and/or disinfecting agent with a sustainable bactericidal effect, such as a CHX solution. | 2015-12-10 |
20150352024 | Oral Hygiene Products and Method of Using the Same - A chewing gum for highly efficient and quick plaque and tartar removal and inhibition including pure ascorbic acid crystals and/or granulars (vitamin C) and an enamel repairing composition such as a blend of hydroxyapatite crystals and sodium fluoride. The chewing gum can contain at least 20% of ascorbic acid without compromising the integrity of tooth enamel because hydroxyapatite will repair any damage to the enamel. | 2015-12-10 |
20150352025 | Compositions and Methods for Providing Long Wearing Film to Keratin Surfaces - A multiple day wear composition for keratin surfaces comprising at least one volatile solvent, at least one crosslinked organosiloxane film former, and from about 5 to 12% of montmorillonite minerals comprising a mixture of bentonite and hectorite wherein the ratio of bentonite to hectorite montmorillonite mineral ranges from about 2 to 4 parts of bentonite to 1 part of hectorite and related methods. | 2015-12-10 |
20150352026 | COMPOSITION FOR INCREASING OF THE EFFECTIVENESS OF UV-B THERAPY, PROCESS FOR THE PREPARATION THEREOF, AND ITS USE - A light-therapeutic composition is disclosed, which can modify the optical characteristics of the skin, thereby increase the effectiveness of the UV-B therapy. The composition according to the invention includes one or more material, which sets the minimum value of wavelength of the light transmitted, one or more material, which is suitable to modify the above-mentioned wavelength value, and increase the transmittance of the skin in a certain wavelength-range, furthermore, optionally an excipient. The composition according to the invention blocks the UV radiation in the wavelength ranging from 280 to 300 nm, and helps the incorporation of the UV radiation by the skin in the wavelength ranging from 310 to 320 nm. | 2015-12-10 |
20150352027 | FLEXIBLE SOLID COSMETIC COMPOSITION COMPRISING ANIONIC SURFACTANTS AND POLYMER CONDITIONING AGENTS, AND COSMETIC TREATMENT METHOD - The present invention relates to an aqueous cosmetic composition in flexible solid form, comprising:
| 2015-12-10 |
20150352028 | SUPERABSORBENT POLYMERS AND SILICONE ELASTOMER FOR USE IN SKIN CARE COMPOSITION - A thickened aqueous composition containing from about 0.01% to about 10%, by weight, of an superabsorbent polymer, from about 0.1% to about 20%, of a silicone elastomer; and from about 20% to about 98% of water. | 2015-12-10 |
20150352029 | HAIR CLEANSING COMPOSITION - The invention provides a hair cleansing composition which contains the following components (a), (b), and (c), component (a) being in the form of particles having a mean particle size of from 0.5 μm to 50 μm, wherein the components (a), (b), and (c) are: | 2015-12-10 |
20150352030 | COMPOSITION - A hair colouring composition comprising analkylated polyethyleneimine dye, wherein the alkylated polyethyleneimine dye comprises a polyethyleneimine having covalently bound to the nitrogen groups of the polyethyleneimine: (i) a negatively charged reactive dye and; (ii) a linear carbon chain comprising at least 7 carbon atoms. | 2015-12-10 |
20150352031 | COMPOSITION - A hair colouring composition comprising an arylated polyethyleneimine dye wherein the arylated polyethyleneimine dye comprises a polyethyleneimine having covalently bound to the nitrogen groups of the polyethyleneimine: a. a negatively charged reactive dye and; b. aryl group or substituted aryl group; c. in which the aryl group or substituted aryl group and the negatively charged reactive dye are different moieties. | 2015-12-10 |
20150352032 | ARTIFICIAL NAIL COMPOSITION, ARTIFICIAL NAIL, METHOD FOR FORMING ARTIFICIAL NAIL, AND NAIL ART KIT - To provide an artificial nail composition that has excellent stability over time and that can give an artificial nail having excellent surface gloss, removability, and adhesion, and to provide an artificial nail, a method for forming an artificial nail, and a nail art kit that employ the artificial nail composition. | 2015-12-10 |
20150352033 | ANTI-ADHERENT FORMULATION INCLUDING AN ANIONIC OR NONIONIC POLYMER - Liquid formulations having anti-adherent properties are disclosed herein. The liquid anti-adherent formulation described herein acts to prevent the adherence of menses and/or fecal material to the skin in the labial and perianal regions during and after menstruation or defecation, respectively. The liquid anti-adherent formulation contains a carrier, a polymer selected from an anionic polymer, nonionic polymer, and combinations thereof. Anti-adherent formulation was found to be effective if a menses leave-on percentage as defined within the Menses Leave-On Percentage Test method described herein of less than 7.2% after two insults. | 2015-12-10 |
20150352034 | Personal Care Products Containing Microalgae or Extracts Thereof - Compositions and methods for their use as personal care products are disclosed. The compositions contain microalgae or microalgal components and are beneficial for use in skin and hair care. | 2015-12-10 |
20150352035 | HIGH UV PROTECTION ALCOHOL-FREE ANHYDROUS CLEAR SYSTEM - The present invention is directed to a composition containing: an emollient system containing esters chosen from dicaprylyl ether, isopropyl myristate, caprylic/capric triglyceride, and sorbitan trioleate; sunscreen actives; an oil-soluble film-former; and optionally, an aesthetic modifier, wherein the composition is clear in appearance both during and after its application onto a keratinous substrate, and alcohol-free. | 2015-12-10 |
20150352036 | COMBINATION OF PLANT EXTRACTS TO IMPROVE SKIN TONE - Disclosed is a composition and methods of its use for whitening skin or evening out skin tone, wherein the composition includes dried navy (haricot)-bean ( | 2015-12-10 |
20150352037 | ANTI-AGING COMPOSITION FOR VITALIZATION OF RETINOIC ACID RECEPTOR THAT CONTAINS MIXED EXTRACT OF CHINESE MATRIMONY VINE AND PINE NEEDLES AS EFFECTIVE COMPONENT - Provided are an anti-aging composition that contains a mixed extract of Chinese matrimony vine and pine needles as an effective component and a method of inhibiting aging of skin. The composition is for an external application to the skin, wherein a mixed extract of Chinese matrimony vine and pine needles, which are the natural ingredients, is contained such that excellent anti-aging or wrinkle improvement effects to the skin can be obtained through the vitalization of a retinoic acid derivative. | 2015-12-10 |
20150352038 | A DOSAGE FORM FOR ADMINISTERING AN ACTIVE PRINCIPLE FOR ACCELERATED SLEEP INDUCTION AND/OR FOR TREATING SLEEP DISORDERS AND/OR FOR TREATING A CENTRAL NERVOUS SYSTEM DISORDER - A dosage form for oral administration, via the mucous membranes, of an active principle for accelerated sleep induction and/or for treating sleep disorders and/or for treating a central nervous system disorder, the active principle being lipophilic or amphiphilic and being in a dissolved state that is stable and complete in a hydro-alcoholic solution having 35% to 70% by weight of ethanol and 30% to 65% by weight of water, generating nanostructures of the active principle under consideration within the hydro-alcoholic solution, thereby enabling the active principle to cross the blood-brain barrier, the active principle being in base and/or salt form and belonging to the chemical families of sleep inducers or modulators of lipophilic or amphiphilic type and of molecular weight that is less than 1000 Da, the active principle being selected from the families of Imidazopyridines, including Zolpidem, the family of Cyclopyrrolones, including Eszopiclone, the family of Pyrazolopyrimidines, including Zaleplon, the family of Benzodiazepines, including Midazolam and Brotizolam, the family of H1-antihistamine sedatives, including Doxylamine and Cyproheptadine, and/or the family of Melatonin and Melatonin agonists, including Melatonin, Ramelteon, and Agomelatine, the volume of the hydro-alcoholic solution being less than or equal to 2 mL, and the active principle being present at a dosage that is less than or equal to 8 mg, all of the active principle being absorbed in transmucosal manner via the mucous membranes of the floor of the oral cavity, in particular via the gums/cheeks, via the gum area, via the cheeks, or under the tongue. | 2015-12-10 |
20150352039 | SONOSENSITIVE LIPOSOME, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND METHOD OF DELIVERING ACTIVE AGENT TO SUBJECT USING THE SONOSENSITIVE LIPOSOME - Provided is a liposome comprising a lipid bilayer and a sonosensitizer that is disposed in and/or on the lipid bilayer, wherein the sonosensitizer self-assembles to form aggregates when exposed to ultrasound; and a method of efficiently delivering an active agent to a target site in the body of a subject using the sonosensitive liposome. | 2015-12-10 |
20150352040 | TOPICAL PERIPHERAL NEURO-AFFECTIVE (TPNA) THERAPY - A method of treating peripheral neuropathic pain in humans resulting from a peripheral nerve injury and for treating muscle spasm in humans resulting from a peripheral nerve injury comprises applying a therapeutically effective amount of a drug selected from the group consisting of a dopamine agonist, a skeletal muscle relaxant, and a combination thereof topically to the site of the injury. | 2015-12-10 |
20150352041 | INJECTABLE DEPOT FORMULATION COMPRISING OPTICALLY ACTIVE TOLVAPTAN AND PROCESS OF PRODUCING THE SAME - This invention provides an injectable formulation to be administered intramuscularly or subcutaneously that is used for the prevention or treatment of polycystic kidney disease, and that can maintain a therapeutically effective blood concentration of tolvaptan for a long period of time; and a process for producing the same. More specifically, this invention relates to an injectable depot formulation comprising (1) a particle containing optically active tolvaptan as an active ingredient and (2) a pharmaceutically acceptable carrier for injection, and a process for producing the same. | 2015-12-10 |
20150352042 | STABLE PARENTERAL DNJ COMPOSITIONS - A stable pharmaceutical composition that includes an active agent selected from 1-deoxynojirimycin, a pharmaceutically acceptable salt thereof, or a derivative thereof, and a buffer, wherein the stable pharmaceutical composition is capable of being parenterally administered to a human without deleterious health effects. Pompe disease is an example of a lysosomal storage disorder. Pompe disease is caused by a deficiency in the enzyme acid alpha-glucosidase (GAA). GAA metabolizes glycogen, a storage form of sugar used for energy, into glucose. | 2015-12-10 |
20150352043 | MICROGRANULAR FORMULATION INCLUDING COAGULATION UNIT COMPRISING DISCONTINUOUS PHASE AND CONTINUOUS PHASE - A pharmaceutical composition which is Rapidly Dissolved in a mouth, comprising
| 2015-12-10 |
20150352044 | SINGLE SERVE BEVERAGE POD CONTAINING CANNABIS - Single-serve containers for use in brewing a | 2015-12-10 |
20150352045 | SKIN ENHANCING BEVERAGE COMPOSITION - The invention provides a beverage composition comprising hydrolysed collagen and vitamin C, or a derivative thereof, which is particularly suitable for improving skin hydration and skin condition. Additional active ingredients may include methyl sulphonyl methane, a vitamin selected from the vitamin B complex, L-lysine, omega-3 and omega-6 fatty acids. The beverage composition is such that it promotes higher absorption and bioavailability of skin-nourishing ingredients. The beverage composition can improve the moisture content of the skin and can prevent fine lines and wrinkles. | 2015-12-10 |
20150352046 | METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES - The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays. | 2015-12-10 |
20150352047 | DRUG DELIVERY MEANS - The invention broadly comprises a chemical composition including a plurality of cholesteryl esters arranged to form a vesicle. In several embodiments, all of the plurality of cholesteryl esters have a same molecular length, which in some embodiments provides a vesicle having a generally smooth outer surface, while in other embodiments, a portion of the plurality of cholesteryl esters have different molecular lengths, which in some embodiments provides a vesicle having a generally irregular outer surface. In yet further embodiments, a shape of the vesicle is selected from the group consisting of spherical, oval, disc-like, tubular and polyhedral shapes, and in yet other embodiments, a wall of the vesicle is selected from the group consisting of a monolayer and a bilayer. In still further embodiments, the chemical composition further includes a polyethylene glycol coat of mixed polymer size. In some embodiments, the plurality of cholesteryl esters include at least two different cholesteryl esters, and in some of these embodiments, the at least two different cholesteryl esters are selected from the group consisting of: cholesteryl myristate, cholesteryl laurate, cholesteryl dodeconate, cholesteryl palmitate, cholesteryl arachidonate, cholesteryl behenate, cholesteryl linoleate, cholesteryl linolenate, cholesteryl oleate and cholesteryl stearate. | 2015-12-10 |
20150352048 | VALSARTAN-AMLODIPINE COMPOUND SOLID PREPARATION AND PREPARATION METHOD THEREFOR - The present invention relates to a compound solid preparation and the preparation method therefor and specifically relates to a valsartan-amlodipine compound solid preparation and the preparation method therefor. The valsartan-amlodipine compound solid preparation comprises valsartan particles and an amlodipine premix. The valsartan particles are prepared by preparing wet valsartan particles from a mixture obtained by mixing valsartan and a pharmaceutic adjuvant with an ethanol aqueous solution as a wetting agent and drying the wet valsartan particles. The amlodipine premix is prepared by mixing amlodipine and a pharmaceutic adjuvant. The valsartan-amlodipine compound solid preparation according to the present invention and the preparation method thereof can prevent the two main ingredients, amlodipine and valsartan, from interfering each other, and the preparation method is relatively simple and suitable for large-scale industrial production. | 2015-12-10 |
20150352049 | PHARMACEUTICAL COMPOSITION FOR PROTECTING WOUNDS, PROVIDING HEMOSTASIS, OR PREVENTING ADHESION IN THE GASTROINTESTINAL TRACT - The present invention provides a pharmaceutical composition in a powder form for providing wound protection, hemostasis, or anti-adhesion in the gastrointestinal tract, which comprises a certain mucoadhesive polymer; and a certain hygroscopic agent. | 2015-12-10 |
20150352050 | BIODEGRADABLE MICROBEADS WITH IMPROVED ANTICANCER DRUG ADSORPTIVITY, CONTAINING ALBUMIN AND DEXTRAN SULFATE, AND PREPARATION METHOD THEREFOR - The present invention relates to: biodegradable microbeads with improved anticancer drug adsorptivity, containing albumin and dextran sulfate; a preparation method therefor; and a method for treating cancer using the same. The microbeads of the present invention is prepared from a biocompatible and biodegradable polymer so as to be safe to the human body, and can effectively inhibit the growth of a tumor by effectively blocking a blood vessel which supplies nutrition to a liver tumor and continuously releasing an anticancer drug adsorbed on surfaces of the beads. Therefore, the present invention can be useful for liver cancer chemoembolization. | 2015-12-10 |
20150352051 | PROLONGED-RELEASE DIPHENIDOL COMPOSITION - A sustained release diphenidol pharmaceutical composition is described, comprising: a) from 15 to 50% diphenidol hydrochloride; b) from 0.1 to 20% of one or more binding agents; c) from 5 to 90% of one or more diluent agents; d) from 5 to 50% of one or more releasing modification agents; e) from 0.25 to 10% of one or more lubricating agents; and f) 0.1 to 10% of one or more gliding agents. | 2015-12-10 |
20150352052 | 2,2',6,6'-TETRAISOPROPYL-4,4'-2-BIPHENOL SOFT CAPSULE AND METHOD FOR PREPARING SAME - Disclosed is a 2,2′,6,6′-tetraisopropyl-4,4′-biphenol soft capsule composed of a capsule shell and the contents in the capsule, wherein the contents in the capsule include 2,2′,6,6′-tetraisopropyl-4,4′-biphenol, a solvent, and an antioxidant, among others. | 2015-12-10 |
20150352053 | PHARMACEUTICAL COMPOSITIONS COMPRISING DGLA AND USE OF SAME - The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders. | 2015-12-10 |
20150352054 | Enteric Soft Capsules - A gel mass is provided that is useful in manufacturing enteric soft or hard capsules, or enteric tablets without coating. | 2015-12-10 |
20150352055 | COMPOSITION COMPRISING AN ENCAPSULATED ANTAGOMIR - The invention relates to a composition comprising an effective amount of at least one inhibitor of a miRNA involved in the angiogenesis, or a precursor thereof, wherein said inhibitor is microencapsulated into polymeric biodegradable and biocompatible microspheres. The invention also relates to the use of the said composition for preventing or treating cardiac disorders, including cardiac disorders caused by ischemy. | 2015-12-10 |
20150352056 | MICROENCAPSULATION TECHNIQUE AND PRODUCTS THEREOF - Inside-out gelation process to generate hydrogel microcapsules (aka microbeads). Methods of encapsulating biological material in the microbead 3-dimensional hydrogel matrix are described herein. The process generally comprises formation of a mixture of a hydrogel precursor compound, an optional biological material, and a divalent cation. The mixture is then combined with alginate, to generate an alginate shell around droplets of the mixture, followed by gelation of the hydrogel precursor core, and removal of the temporary alginate shell to yield self-sustaining microbeads. | 2015-12-10 |
20150352057 | METHOD OF USING PEELABLE FILM-FORMING COMPOSITION - The compositions and methods of this invention relate to peelable film-forming compositions that may be applied to and removed from the skin containing polyvinyl alcohols and adhesion-enhancing polymers. | 2015-12-10 |
20150352058 | TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING DONEPEZIL - The present invention provides a transdermal drug delivery system comprising a drug-containing matrix layer comprising: (a) donepezil or a pharmaceutically acceptable salt thereof as an active ingredient; and (b) an acrylate-rubber hybrid as an adhesive. | 2015-12-10 |
20150352060 | NOVEL TREATMENT OF PROSTATE CARCINOMA - Disclosed herein are naphthoquinone analogs, such as plumbagin, pharmaceutical compositions that include naphthoquinone analogs, such as plumbagin, and methods of treating diseases and/or conditions such as cancer with naphthoquinone analogs, such as plumbagin. Also included are combination therapies wherein a naphthoquinone analog, such as plumbagin, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer. | 2015-12-10 |
20150352062 | METHODS AND SYSTEMS FOR TREATING OVERWEIGHT INDIVIDUALS - A system for inducing weight loss in an individual includes a collection having plurality of dose units therein. Each dose unit includes a first dose of phentermine or a second dose of phentermine. The first dose is greater than the second dose, and the collection includes at least one first dose and at least one second dose. | 2015-12-10 |
20150352063 | Drug for Killing Acid-Fast (Red) Bacillus - Disclosed is a drug for killing acid-fast (red) | 2015-12-10 |
20150352064 | METHOD OF TREATING DELAYED HEALING OF A WOUND ASSOCIATED WITH DIABETES - The method of treating delayed healing of a wound associated with diabetes includes administering to the wound a composition comprising an anti-senescence compound and a pharmaceutically acceptable carrier. The anti-senescence compound may be 18α-Glycyrrhetinic acid, a Caveolin-1 (Cav-1) inhibitory compound, or a Polymerase I Transcript Release Factor (PTRF-1) inhibitory compound. The anti-senescence compound may be effective in preventing and/or reversing premature cellular senescence. The anti-senescence compound may be effective in promoting healing of a wound, e.g., delayed or incompletely healed wound. The anti-senescence compound may be effective in promoting healing of a delayed healing wound or chronic wound of a diabetic patient, such as a diabetic ulcer or venous ulcer. | 2015-12-10 |
20150352065 | METHODS OF TREATMENT OF FIBROSIS AND CANCERS - The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethyl-methyloxyphenyl]prop-2-en-1-one for treating fibrotic diseases and cancers. | 2015-12-10 |
20150352066 | Solid Pharmaceutical Compositions Containing Pregabalin - A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone. | 2015-12-10 |
20150352067 | AGENT FOR ELEVATING NITRIC OXIDE CONCENTRATION - An agent for elevating nitric oxide (NO) concentration comprising glutathione or a salt thereof as an active ingredient; an agent for elevating NO concentration comprising glutathione or a salt thereof as an active ingredient for preventing or ameliorating a vascular endothelial malfunction-related symptom, or dilating blood vessels or promoting blood flow by elevating NO concentration; and a method for elevating NO concentration by ingesting glutathione or a salt thereof. | 2015-12-10 |
20150352068 | ORAL FORMULATIONS OF BIPOLAR TRANS CAROTENOIDS - The subject invention relates to a variety of formulations of bipolar trans carotenoids including pharmaceutical compositions for oral delivery of a bipolar trans carotenoid comprising i) a bipolar trans carotenoid, ii) a cyclodextrin, and iii) a coating. The invention also relates to preparation of such formulations and their uses. | 2015-12-10 |
20150352069 | Use of Protectin DX for the Stimulation of Muscular IL-6 Secretion - The present invention provides a method for the stimulation of secretion or expression of muscular IL-6 in a subject with the administration of Protectin DX (PDX). Particularly, the increase in circulating levels of IL-6 originating from the subject muscles is useful for regulating blood glucose and suppressing lipid-induced inflammation and other related inflammatory conditions such as insulin resistance, metabolic syndrome, type-2 diabetes, hypertension and cardiovascular diseases. Alternatively, the increase in muscular IL-6 expression in a subject may also be useful for increasing energy supply during exercise, or facilitating muscular recovery after strenuous effort. | 2015-12-10 |
20150352070 | METHODS OF TREATING DISEASES ASSOCIATED WITH HIGH-FAT DIET AND VITAMIN A DEFICIENCY USING RETINOIC ACID RECEPTOR AGONISTS - This invention relates to pharmaceutical composition and methods of using vitamin A and/or RARB agonist for the treatment or prevention of diseases or conditions associated with high fat diet and/or vitamin deficiency. After smoking, high fat diet is said to be the second most lethal habit, causing 300,000 deaths each year in the U.S. alone. High fat diet leads to many health problems, including obesity, stroke, cancer, high blood pressure, diabetes, osteoarthritis, rheumatoid arthritis, multiple sclerosis, heart disease, and diseases in other organs such as liver and kidney. | 2015-12-10 |
20150352071 | METHODS FOR REDUCING MUSCLE SORENESS AFTER EXERCISE USING BETA-HYDROXY-BETA-METHYLBUTYRATE - Nutritional compositions containing beta-hydroxy-beta-methylbutyrate (HMB) are administered to an individual to reduce muscle soreness after exercise. The compositions contain a source of HMB; a protein source with at least about 21% branched-chain amino acids, by weight of total protein in the protein source; and a carbohydrate blend which contains a combination of rapid release and sustained release carbohydrates. | 2015-12-10 |
20150352073 | Chromone Inhibitors of S-Nitrosoglutathione Reductase - The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same. | 2015-12-10 |
20150352074 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY - Novel substituted chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described. | 2015-12-10 |
20150352075 | Treatment of Alzheimer's and Cognitive Impairment With Andrographolides - We found that Andrographolide binds to GSK-3β: | 2015-12-10 |
20150352076 | MOLECULARLY TARGETED COMBINATION DRUG FOR TUMOR TREATMENT AND PREVENTION - To provide means for treating and preventing a wide variety of cancers and tumors, including cancer in which there is PI3K/Akt pathway activation or p53 deactivation, or tumors for which chemotherapy, radiation therapy, hormone therapy, and other such conventional treatment methods have low effectiveness, different molecularly targeted drugs such as OBP-801 and PI3K inhibitor—preferably LY294002, BKM120, GDC-0941, BEZ235, BYL719, or CH5132799—are used in combination. This makes it possible to simultaneously obtain a plurality of different marked pharmaceutical benefits which are synergistic, not being obtainable through use of a formulation with either of the respective molecularly targeted drugs alone, such as caspase pathway activation, enhanced expression of Bim, increased accumulation of intracellular reactive oxygen species, and suppressed expression of survivin and XIAP protein, and makes it possible to provide new and clinically effective tumor treatment/prevention strategies. | 2015-12-10 |
20150352077 | Multi-Component Crystalline Particles for Inhalation Therapy - Pharmaceutical Preparations Multi-component crystalline particles and compositions, methods for their preparation, their uses in inhalation therapy and inhaler devices containing said particles are provided, in particular particles comprising glycopyrrolate. The particles can be prepared substantially free of excipients and agents other than active agents or their precursors in the presence of ultrasonic irradiation in a process comprising contacting a solution in a first flowing stream with an anti-solvent in a re-circulating second flowing stream, causing the mixing thereof and collecting crystals that are generated. | 2015-12-10 |
20150352078 | PHARMACEUTICAL COMPOSITION FOR DISEASES CAUSED BY PATHOGENIC MICROORGANISMS SUCH AS CANDIDA - An object is to provide means for precisely treating vaginitis caused by intracellular parasite, protozoa, and/or fungus. A pharmaceutical composition for vaginitis, comprising a compound represented by the following general formula (1) as an active ingredient: (1) (In the formula, R represents a halogen atom or a hydrogen atom, and X represents a halogen atom.) | 2015-12-10 |
20150352079 | SELECTIVE HISTONE DEACETYLASE 8 INHIBITORS - Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that benefit from inhibition of HDAC8 activity | 2015-12-10 |
20150352080 | BIOAVAILABLE COMPOSITIONS OF METAXALONE COMPRISING NONVOLATILE LIQUIDS AND PROCESSES FOR PRODUCING THE SAME - Pharmaceutical compositions comprising metaxalone which demonstrate improved dissolution and bioavailability characteristics compared to the commercially available product, and methods of producing them are provided. In a preferred embodiment, a dosage form comprising metaxalone and at least one inactive powder excipient is bioequivalent to its commercially available counterpart (Skelaxin® 400-mg tablets) after oral administration to fasting or non-fasting human subjects, while at the same time displaying faster drug dissolution rates than the Skelaxin® tablets as demonstrated from three different dissolution tests. In another preferred embodiment, a dosage form comprising metaxalone, at least one inactive powder excipient and a nonvolatile liquid is significantly more bioavailable than the commercially available Skelaxin® 400-mg tablets after oral administration to fasting human subjects. | 2015-12-10 |
20150352081 | USE OF PIDOTIMOD TO TREAT ATOPIC DERMATITIS - The present invention is directed to the use of pidotimod, or a physiologically acceptable salt thereof, to treat atopic dermatitis. For the treatment of the present invention, pidotimod, or a physiologically acceptable salt thereof, is preferably administered topically. | 2015-12-10 |
20150352082 | SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES - The invention relates to a family of differently substituted benzothiazoles having inhibitory activity against casein kinase 1 (CK-1) enzyme, as a result of which they are suitable for use in the treatment or prevention of diseases caused by this enzyme, particularly diseases associated with circadian rhythm and inflammatory, autoimmune, psychiatric, neurodegenerative, neurological or ophthalmic diseases, as well as for inducing cell regeneration | 2015-12-10 |
20150352083 | Mast Cell Stabilizers to Prevent or Treat Laminitis - Provided herein are mast cell stabilizers used to prevent, treat, or mitigate severity of laminitis. Mast cell stabilizers can be combined with antihistamines and other medicaments to prevent, treat, or mitigate severity of laminitis. | 2015-12-10 |
20150352084 | COMPOSITIONS AND METHODS FOR TREATING MIDDLE-OF-THE-NIGHT INSOMNIA - The present invention provides liquid dosage forms for treating narcolepsy. The liquid dosage form includes zolpidem or a pharmaceutically acceptable salt thereof, a carbonate salt, a metal oxide, and a borate salt. The present invention also provides methods for treating somnambulism. The methods include administering an emulsion that includes zolpidem, a bicarbonate salt, a citrate salt, and a phosphate salt. | 2015-12-10 |
20150352085 | METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA - Methods of increasing tonic inhibition in a subject in need thereof, for example a subject with Fragile X syndrome or Angelman syndrome are disclosed. Methods of treating secondary insomnia in a subject with a neurodegenerative disease or disorder are also disclosed. The methods can include administering the subject an effective amount of 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) or a derivative thereof, or a pharmaceutically acceptable salt thereof, increase tonic inhibition in neurons of the subject; to increase slow wave sleep (SWS) and/or slow wave activity (SWA), normalize sleep architecture, reduce secondary insomnia, increase non-rapid eye movement (NREM) sleep, increase sleep continuity, enhance delta activity within NREM, increase or improve total sleep time (TST), increase or improve sleep efficiency, reduce total time awake (TAA), reduce number of awakenings (NWA), reduce latency to persistent sleep (LPS), or to reduce wake after sleep onset (WASO), in the subject, or any combination thereof. | 2015-12-10 |
20150352086 | HEAT SHOCK PROTEIN (HSP) INHIBITION AND MONITORING EFFECTIVENESS THEREOF - Provided herein are methods of treating a BRAF inhibitor resistant cancer in a subject. Also provided are methods of monitoring or evaluating the treatment of a cancer in a subject. Further provided are methods of diagnosing a cancer or disease associated with antibody production in a subject. | 2015-12-10 |
20150352087 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE - This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[3,4-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 2015-12-10 |
20150352088 | Bis-Quaternary Ammonium Cyclophane Compounds that Interact with Neuronal Nicotinic Acetylcholine Receptors - Provided are bis-quaternary ammonium cyclophane compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and or gastrointestinal tract disorders. | 2015-12-10 |
20150352089 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE - The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: | 2015-12-10 |
20150352090 | CARBAMATE DERIVATIVES - Compounds of formula (I) defined herein are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract. | 2015-12-10 |
20150352091 | AMINOESTER DERIVATIVES - Compounds of formula (I), defined herein, are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of a disease of the respiratory tract. | 2015-12-10 |
20150352092 | METHYL/FLUORO-PYRIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS AND FLUORO-PYRIMIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS - The present disclosure provides methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds useful in the treatment of p38 kinase mediated diseases, such as lymphoma and auto-inflammatory disease, including rheumatoid arthritis, having the structure of Formula (I): | 2015-12-10 |
20150352093 | Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones - The present invention provides dosing regimens for administering pharmacological chaperones to a subject in need thereof. The dosing regimens can be used to treat disorders caused by improper protein misfolding, such as lysosomal storage disorders. | 2015-12-10 |
20150352094 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES - The invention relates to fatty acid niacin conjugates; compositions comprising an effective amount of a fatty acid niacin conjugate; methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid niacin conjugate, and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid niacin conjugate and another therapeutic agent. | 2015-12-10 |
20150352095 | Tetomilast Polymorphs - The present invention provides a tetomilast crystal that is industrially easily produced in a large volume. (1) a tetomilast hydrate crystal having a power X-ray diffraction spectrum that is substantially the same as the powder X-ray diffraction spectrum shown in FIG. | 2015-12-10 |
20150352096 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS - Compounds of the formula Ia***** | 2015-12-10 |
20150352097 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES - The present invention relates to a compositions for and methods of cancer treatment in which compounds of Formula I or Formula II. In some aspects, the treatment of B-cell Lymphoma or other hematopoietic cancers is encompassed. In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more compounds of Formula I or Formula II. Combination therapy with, for example, a class of therapeutics known as 26S proteasome inhibitors, for example, Bortezomib, are also included. In another aspect the present invention relates to autoimmune treatment with compounds of Formula I or Formula II. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease. | 2015-12-10 |
20150352098 | SUBSTITUTED PYRANO AND FURANOQUINOLINES, THEIR PREPARATION AND USE AS MEDICAMENTS - The present invention relates to new substituted pyrano and furanoquinolines having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments. | 2015-12-10 |
20150352099 | Compositions and Methods of Reducing Sedation - Methods and compositions useful in reducing drug-induced sedation in subjects. | 2015-12-10 |
20150352101 | USE OF LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF VASCULITIS - The embodiments described herein include methods and formulations for treating vasculitis. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient. | 2015-12-10 |
20150352102 | USE OF LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF ANAPHYLAXIS - The embodiments described herein include methods and formulations for treating anaphylaxis and related acute allergic reactions. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient. | 2015-12-10 |
20150352103 | USE OF LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF AUTOIMMUNE DISORDERS - The embodiments described herein include methods and formulations for treating autoimmune disorders. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient. | 2015-12-10 |
20150352104 | USE OF LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF TRAUMATIC INJURY - The embodiments described herein include methods and formulations for treating lung and brain injury. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient. | 2015-12-10 |
20150352105 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY - Methods are provided of treating cardiac hypertrophy in a mammalian subject comprising administering to the subject an anti-hypertrophic effective amount of an ion channel TR-PV1 inhibitor. The methods include treatment of a symptom of cardiac hypertrophy in the subject comprises cardiac remodeling, cardiac fibrosis, apoptosis, hypertension, or heart failure | 2015-12-10 |
20150352106 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE - The present invention provides a nitrogen-containing heterocyclic compound or a pharmaceutically acceptable salt thereof having an inhibitory effect on the production of kynurenine, represented by formula (I): | 2015-12-10 |
20150352107 | ALPHA7 NEURONAL NICOTINIC RECEPTOR LIGAND AND ANTIPSYCHOTIC COMPOSITIONS - The present invention relates to a composition comprising an antipsychotic and an α7 nicotinic acetylcholine receptor ligand, a method of using the same, and a related article of manufacture. | 2015-12-10 |
20150352108 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON - The invention relates to certain amino-pyrimidine compounds which inhibit TBK1 and/or IKK epsilon and which may therefore find application in treating inflammation, cancer, septic shock and/or Primary open Angle Glaucoma (POAG). | 2015-12-10 |
20150352109 | KINASE INHIBITOR AND METHOD FOR TREATMENT OF RELATED DISEASES - Disclosed is a compound of (aminophenylamino) pyrimidyl benzamides and a synthesis method thereof. The compound has Btk-inhibition activity and can be used to treat autoimmune diseases, heteroimmune diseases, cancers or thromboembolic diseases. | 2015-12-10 |
20150352110 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS - The present invention relates to novel oxindole derivatives of the general formula (I) to medicaments comprising them and to their use for the prophylaxis and/or treatment of diseases vasopressin dependent. | 2015-12-10 |
20150352111 | Therapeutic Indications of Kinase Inhibitors - Disclosed herein are compounds, compositions, and methods for preventing and treating diseases associated with protein kinase activity. The therapeutic indications described herein relate to receptor tyrosine kinase (RTK) inhibition for the treatment or prevention of vascular conditions and proliferative disorders. The disclosure also relates to irreversible RTK inhibitors. | 2015-12-10 |
20150352112 | VORICONAZOLE INCLUSION COMPLEXES - The present invention relates to new voriconazole formulations comprising 2-hydroxypropyl-□-cyclodextrins and the preparation thereof. | 2015-12-10 |
20150352113 | TREATMENT OF ASTROCYTES-TUMOR CELLS INHIBITORS OF ENDOTHELIN RECEPTORS - The disclosure relates to an endothelin receptor antagonist for use in the prevention or treatment of brain metastases in combination with a cytotoxic chemotherapy agent, radiotherapy or both. The endothelin receptor antagonist may for example be bosentan, macitentan or a mixture of bosentan and macitentan. | 2015-12-10 |